In this phase IIb clinical trial, PDGF antagonist E10030 was administered in combination with the anti-vascular endothelial growth factor drug ranibizumab (Lucentis) in the treatment of neovascular age-related macular degeneration, showing a favorable safety and efficacy profile. Here, VEGFA is linked to age-related macular degeneration.